We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRTX
1901
TPG RE Finance Trust
TRTX
$606M
| $1.54M | ﹤0.01% |
76,036
+1,381
| +2% | +$27.8K |
|
|
EBSB
1902
DELISTED
Meridian Bancorp, Inc.
EBSB
| $1.53M | ﹤0.01% |
76,168
+999
| +1% | +$19.6K |
|
1903
American Public Education
APEI
$931M
| $1.52M | ﹤0.01% |
55,517
+1,614
| +3% | +$39.4K |
|
|
CCRN
1904
DELISTED
Cross Country Healthcare
CCRN
| $1.5M | ﹤0.01% |
129,549
+6,228
| +5% | +$70.3K |
|
1905
Orion
OEC
$429M
| $1.5M | ﹤0.01% |
77,643
+1,557
| +2% | +$28.1K |
|
1906
Theravance Biopharma
TBPH
$877M
| $1.5M | ﹤0.01% |
57,916
+1,141
| +2% | +$22.2K |
|
|
CIVI
1907
DELISTED
Civitas Resources
CIVI
| $1.5M | ﹤0.01% |
64,037
+3,364
| +6% | +$66.6K |
|
|
MAXR
1908
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $1.49M | ﹤0.01% |
95,354
+1,825
| +2% | +$19K |
|
|
SFIX
1909
Stitch Fix
SFIX
$538M
| $1.49M | ﹤0.01% |
58,114
+5,562
| +11% | +$129K |
|
1910
Powell Industries
POWL
$7.55B
| $1.49M | ﹤0.01% |
91,179
+3,807
| +4% | +$53.4K |
|
1911
Kosmos Energy
KOS
$1.47B
| $1.48M | ﹤0.01% |
260,217
-782
| -0.3% | -$4.72K |
|
1912
Hawkins
HWKN
$2.71B
| $1.48M | ﹤0.01% |
64,410
+2,590
| +4% | +$54.8K |
|
1913
Unitil
UTL
$981M
| $1.47M | ﹤0.01% |
23,786
+318
| +1% | +$19.7K |
|
|
AERI
1914
DELISTED
Aerie Pharmaceuticals
AERI
| $1.47M | ﹤0.01% |
60,608
+2,374
| +4% | +$49.2K |
|
|
AMAG
1915
DELISTED
AMAG Pharmaceuticals
AMAG
| $1.46M | ﹤0.01% |
120,189
+5,339
| +5% | +$58.3K |
|
1916
PennyMac Financial
PFSI
$4B
| $1.46M | ﹤0.01% |
42,924
+4,156
| +11% | +$135K |
|
1917
German American Bancorp
GABC
$1.91B
| $1.46M | ﹤0.01% |
40,928
+699
| +2% | +$23.4K |
|
|
RDUS
1918
DELISTED
Radius Health, Inc.
RDUS
| $1.46M | ﹤0.01% |
72,336
+4,618
| +7% | +$112K |
|
|
FFG
1919
DELISTED
FBL Financial Group
FFG
| $1.46M | ﹤0.01% |
24,729
+96
| +0.4% | +$5.52K |
|
1920
Groupon
GRPN
$955M
| $1.46M | ﹤0.01% |
30,440
+367
| +1% | +$20.4K |
|
1921
Malibu Boats
MBUU
$562M
| $1.45M | ﹤0.01% |
35,505
+660
| +2% | +$23.9K |
|
1922
IMAX
IMAX
$2.73B
| $1.45M | ﹤0.01% |
71,134
+767
| +1% | +$16.4K |
|
1923
Red Robin
RRGB
$156M
| $1.45M | ﹤0.01% |
43,959
+2,154
| +5% | +$63.6K |
|
1924
Inspire Medical Systems
INSP
$1.7B
| $1.45M | ﹤0.01% |
19,538
+340
| +2% | +$21.9K |
|
|
TUP
1925
DELISTED
Tupperware Brands Corporation
TUP
| $1.44M | ﹤0.01% |
168,147
+8,652
| +5% | +$94.3K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.